Pharmacotherapy of myelodysplastic syndromes

Bibliography

• Hellström-Lindberg E, Gulbrandsen N, Lindberg G, A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037-46
   PubMed Web of Science ®Google Scholar
• Park S, Grabar S, Kelaidi C, Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111(2):574-82
   PubMedGoogle Scholar
• Saiki JH, Bodey GP, Hewlett JS, Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study. Cancer 1981;47:1739-42
   PubMed Web of Science ®Google Scholar
• Karon M, Sieger L, Leimbrock S, 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood 1973;42:359-65
   PubMed Web of Science ®Google Scholar
• Levi JA, Wiernik PH. A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia. Cancer 1976;38:36-41
   PubMed Web of Science ®Google Scholar
• Vogler WR, Miller DS, Keller JW. 5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia. Blood 1976;48:331-7
   PubMed Web of Science ®Google Scholar
• Issa JP, Garcia-Manero G, Giles FJ, Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-7
   PubMed Web of Science ®Google Scholar
• Zagonel V, Lo Re G, Marotta G, 5-Aza-2′-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 1993;7(Suppl 1):30-5
   PubMedGoogle Scholar
• Sigalotti L, Altomonte M, Colizzi F, 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood 2003;101:4644-6
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40
   PubMed Web of Science ®Google Scholar
• Wijermans P, Lübbert M, Verhoef G, Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-62
   PubMed Web of Science ®Google Scholar
• Wijermans PW, Lübbert M, Verhoef G, An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005;84(Suppl 1):9-17
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-803
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-903
   PubMed Web of Science ®Google Scholar
• Borthakur G, Ahdab SE, Ravandi F, Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008;49:690-5
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellström-Lindberg E, Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-9
   PubMed Web of Science ®Google Scholar
• Lyons RM, Cosgriff TM, Modi SS, Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009;27:1850-6
   PubMed Web of Science ®Google Scholar
• Martin MG, Walgren RA, Procknow E, A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol 2009;84:560-4
   PubMedGoogle Scholar
• Steensma DP, Baer MR, Slack JL, Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27:3842-8
   PubMed Web of Science ®Google Scholar
• Raza A, Gezer S, Mundle S, Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268-76
   PubMed Web of Science ®Google Scholar
• Raza A, Mundle S, Shetty V, Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996;63:265-78
   PubMed Web of Science ®Google Scholar
• Raza A, Gregory SA, Preisler HD. The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. Leuk Res 1996;20:881-90
   PubMed Web of Science ®Google Scholar
• Mundle SD, Ali A, Cartlidge J, Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol 1999;60:36-47
   PubMed Web of Science ®Google Scholar
• Raza A, Meyer P, Dutt D, Thalidomide produces transfusion independence in long standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-65
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 2005;93:613-19
   PubMed Web of Science ®Google Scholar
• Galili N, Raza A. Immunomodulatory drugs in myelodysplastic syndromes. Expert Opin Investig Drugs 2006;15:805-13
   PubMedGoogle Scholar
• List A, Kurtin S, Roe DJ, Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, ; for the Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65
   PubMed Web of Science ®Google Scholar
• Göhring G, Giagounidis A, Büsche G, Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol 2010;89:365-74
   PubMed Web of Science ®Google Scholar
• Raza A, Reeves JA, Feldman EJ, Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:86-93
   PubMed Web of Science ®Google Scholar
• Malcovati L, Porta MG, Pascutto C, Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-603
   PubMed Web of Science ®Google Scholar
• Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007;31(Suppl 3):S7-9
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Porter J, El-Beshlawy A, on behalf of the EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010;95(4):557-66
   Google Scholar
• Gatterman N. Assessing the guidelines on iron chelation in MDS – where are we? Leuk Res 2009;(Suppl 1):S22-3
   Google Scholar
• Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 2009;114:5251-5
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009;15:3918-26
   PubMed Web of Science ®Google Scholar
• Gore SD, Weng LJ, Figg WD, Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2002;8:963-70
   PubMed Web of Science ®Google Scholar
• Raffoux E, Chaibi P, Dombret H, Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005;90:986-8
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Yang H, Bueso-Ramos C, Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111:1060-6
   PubMed Web of Science ®Google Scholar
• Raza A, Galili N, Callander N, Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol 2009;2:20
   PubMedGoogle Scholar
• Raza A, Galili N, Smith S, Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood 2009;113:6533-40
   PubMed Web of Science ®Google Scholar
• Braun T, Fenaux P. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 2008;141:576-86
   PubMed Web of Science ®Google Scholar
• Fenaux P, Raza A, Mufti GJ, A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007;109:4158-63
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Fenaux P, Sekeres MA, Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010;28(3):437-44
   Google Scholar
• Deeg HJ, Gotlib J, Beckham C, Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 2002;16:162-4
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Risitano AM, Sloand EM, A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 2002;117:119-26
   PubMed Web of Science ®Google Scholar
• Raza A, Candoni A, Khan U, Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 2004;45:2099-104
   PubMed Web of Science ®Google Scholar
• Issa JP, Castoro R, Randomized phase II study of combined epigenetic therapy: decitabine vs decitabine and valproic acid in MDS and AML. ASH Annual Meeting Abstracts. Blood 2008:112: abstract 228
   PubMedGoogle Scholar
• Voso MT, Santini V, Finelli C, Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009;15:5002-7
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-9
   PubMed Web of Science ®Google Scholar
• Silverman LR, Verma A, Odchimar-Reissig R, A phase I/II study of vorinostat an oral histone deacetylase inhibitor, in combination with azacitidine in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Initial results of a phase I trial: a New York Cancer Consortium. J Clin Oncol 2008: abstract 7000
   Google Scholar
• Sekeres MA, List AF, Cuthbertson D, Final results from a phase 1 combination study of lenalidomide and azacitidine in patients with higher risk myelodysplastic syndromes (MDS). ASH Annual Meeting Abstracts. Blood 2008;112: abstract 221
   Google Scholar
• Scott BL, Ramakrishnan A, Storer B, Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br J Haematol 2010. [Epub ahead of print]
   Google Scholar
• Gore SD, Baylin S, Sugar E, Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66:6361-9
   PubMed Web of Science ®Google Scholar
• Maslak P, Chanel S, Camacho LH, Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 2006;20:212-17
   PubMed Web of Science ®Google Scholar
• Fandy TE, Herman JG, Kerns P, Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114:2764-73
   PubMed Web of Science ®Google Scholar
• Ebert BL, Galili N, Tamayo P, An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008;5:e35
   PubMed Web of Science ®Google Scholar
• Raza A, Mehdi M, Mumtaz M, Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 2008;113:1596-604
   PubMed Web of Science ®Google Scholar
• Estey E. ‘Fairest of them all’ for myelodysplastic syndromes. Blood 2008;111:6
   Google Scholar